Multiple Sclerosis
Cannabinoid-mediated neuroprotection results from interferon-gamma treatment
Published in Proteomics Weekly, January 3rd, 2005
Multiple sclerosis is increasingly recognized as a neurodegenerative disease which is triggered by inflammation in the central nervous system (CNS). Demyelination-associated axonal or neuronal damage is a primary cause of disability and has thus far not been successfully targeted by available drug therapies.
The neuroprotective properties of both endogenous and administered cannabinoids have been shown in in vivo and in vitro models of CNS damage following excitotoxic,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
Source: Proteomics Weekly (2005-01-03)
More Articles from Proteomics Weekly
- Alzheimer Disease
Electrophoresis used to study aggregation of beta-amyloid 1-42 and 1-40 peptides - Cystic Fibrosis
Chaperones function in transmembrane conductance regulator degradation - Neuroscience
MeCP2 may be associated with X-linked delayed-onset neurobehavioral disorders - Oncology
Lipoplex-based transfer of p75 neurotrophin receptor inhibits prostate cancer - Proteomics
Functional interaction between protein- and DNA-binding proteins revealed - Proteomics
Gamma-secretase complex functioning analyzed, presenilin 1 C terminus required - More from this issue of Proteomics Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
